A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Study sponsor: Travere Therapeutics, Inc. · TVTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-10-14Actual
Enrollment · participants48Actual
Source updated2025-11-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.